semaglutide and nonarteritic anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association | BMC Ophthalmology Semaglutide (Wegovy, Ozempic and Rybelsus):

Both dietary approaches, when integrated with semaglutide therapy, have the potential to preserve lean body mass, reduce gastrointestinal adverse events, and enhance adherence through improved satiety and tolerability

It causes uncomfortable symptoms after you eat.

PlexusDx helps determine your optimal treatment timeline through precision testing

A new commentary published in Diabetes, Obesity and Metabolism shares practical recommendations for gathering real world evidence on the use of GLP-1 medications in people with Prader-Willi syndrome

Outcomes included total and early-phase (060min) areas under the curve (AUCs) and peak concentrations

Learn how it works, how much weight to expect to lose, side effects, and who should not use it.